Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.

@article{Browne2011InhibitionOI,
  title={Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.},
  author={Brigid C. Browne and John Crown and Natarajan Venkatesan and Michael J. Duffy and Martin M. Clynes and Dennis Slamon and Norma O'Donovan},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 1},
  pages={68-73}
}
BACKGROUND although trastuzumab has improved the prognosis for HER-2-positive breast cancer patients, not all HER-2-positive breast tumours respond to trastuzumab treatment and those that initially respond frequently develop resistance. Insulin-like growth factor-1 receptor (IGF1R) signalling has been previously implicated in trastuzumab resistance. We tested IGF1R inhibition to determine if dual targeting of HER-2 and IGF1R improves response in cell line models of acquired trastuzumab… CONTINUE READING
51 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

Similar Papers

Loading similar papers…